Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

New RAD202 data confirms positive tumor uptake

Monday, March 17, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has announced new data confirming positive tumor uptake for RAD202. This development is expected to enhance the therapeutic potential of the compound in clinical settings. The results indicate a favorable response in patients, which could lead to further advancements in cancer treatment strategies.
Price reaction · baseline $5.8 (2025-03-14 close) · hit pre-market · clean, no other RADX news in the window
day 0 close · peak
+6.9%
day 1
-2.8%
day 3
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • New data confirms positive tumor uptake for RAD202.
  • The study shows promising results in clinical applications.
  • Potential for significant advancements in cancer treatment.

Full Press Release Details

• Announcements
• Price Sensitive
• March 17, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• October 22, 2022
• Announcements
• December 9, 2022
• Announcements
• June 15, 2022
• Announcements
• July 16, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is RAD202?

RAD202 is a therapeutic compound developed by Radiopharm Theranostics targeting tumor uptake.

What were the results of the RAD202 study?

The study confirmed positive tumor uptake, indicating promising results for cancer treatment.

Who is developing RAD202?

RAD202 is being developed by Radiopharm Theranostics, a company focused on cancer therapies.

What is the significance of the new data?

The new data suggests potential advancements in the effectiveness of cancer treatments.

Tags: RADX Viatris Investor Conferences Healthcare RAD202 Radiopharm Theranostics cancer treatment clinical study tumor uptake
Last updated: Mar 17, 2025